Chemistry:ABT-436
From HandWiki
Short description: Chemical compound
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| Identifiers | |
| CAS Number | |
| UNII | |
ABT-436 is an orally active, highly selective vasopressin V1B receptor antagonist which was under development by Abbott Laboratories and AbbVie for the treatment of major depressive disorder, anxiety disorders, and alcoholism but was discontinued.[1][2][3] It reached phase II clinical trials prior to the discontinuation of its development.[1][3]
See also
- Balovaptan
- Nelivaptan
- SRX-246
- TS-121
References
- ↑ 1.0 1.1 "ABT 436". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800031610.
- ↑ "In vitro characterization of the selective vasopressin V1b receptor antagonists ABT-436 and ABT-558.". Proceedings of Society for Neuroscience. Washington DC, USA. 2008. p. Abstract 560.
- ↑ 3.0 3.1 "A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence". Neuropsychopharmacology 42 (5): 1012–1023. April 2017. doi:10.1038/npp.2016.214. PMID 27658483. PMC 5506792. https://zenodo.org/record/1233482.
 |  |
